The new personalized treatment plan offered by MindSet promises to revolutionize the treatment of mental health conditions. The PrTMS method uses repetitive transcranial magnetic stimulation (rTMS) to adjust brain frequencies and treat conditions such as depression, anxiety, PTSD, OCD, sleep disorders, migraine, addiction, ADD/ADHD, and autism.
PrTMS improves outcomes by building a customized treatment program for each patient. MindSet has used three steps to optimize PrTMS results. The first step entails mapping brainwave activity using an electroencephalogram (EEG). This allows an accurate image of the brain's electrical activity, enabling the identification of brain arrhythmias.
The PrTMS method uses cutting-edge technology to create a personalized treatment program that caters to each patient's unique brainwave pattern and significantly improves the effectiveness of the therapy.
The second step involves using the AI program to analyze the EEG image and determine an appropriate treatment plan. Finally, the third step involves the administration of the rTMS therapy using the personalized treatment plan for optimal results.
The PrTMS method has been used to treat depression and other mental health conditions. With the use of AI, MindSet is taking a significant step forward in the treatment of brain arrhythmias that lead to mental health conditions.
MindSet has set in motion the potential for a new era of treating mental health conditions using PrTMS. The personalized treatment plan brings new hope for patients who have struggled for years with conventional treatments. With the breakthrough created by MindSet, the future of mental health treatment looks brighter.
About MindSet
At MindSet, we are treating the source of a “brain arrhythmia” and not the symptom of the condition. By addressing these underlying issues, our PrTMS treatment aims to help restore normal brain function, reduce symptoms, and improve the quality of life for our patients. Our approach offers a safe, non-invasive, drug-free alternative that has helped over 3,000 patients with various neurocognitive disorders.
